GlassScriptPhysician profile
Jill M Perry
NPI 1548481179
$4,143.62
in general payments reported to CMS, 2019-2025
33 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,246 · 2020: $280 · 2021: $301 · 2022: $345 · 2023: $805 · 2024: $692 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,971.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $959.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $560.83 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $437.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $354.08 | 2019-2025 | |
| Lilly USA, LLC | $292.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $167.15 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $160.94 | 2020-2024 | Glassia |
| Novartis Pharmaceuticals Corporation | $145.29 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $139.71 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Glaxosmithkline, LLC. | $136.38 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $113.24 | 2019-2024 | Eliquis, Camzyos |
| Astellas Pharma US INC | $113.17 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.72 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Teva Pharmaceuticals USA, INC. | $68.19 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $59.61 | 2019-2025 | Spravato |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $38.22 | 2023-2024 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $35.76 | 2022-2023 | Qelbree |
| Shire North American Group INC | $31.86 | 2019 | |
| Currax Pharmaceuticals LLC | $31.20 | 2022-2023 | Onzetra Xsail, Contrave |
| Seqirus USA INC | $30.31 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Abbott Laboratories | $19.48 | 2019 | |
| Sanofi Pasteur INC. | $19.22 | 2023 | |
| Jazz Pharmaceuticals INC. | $19.17 | 2021 | |
| Ironshore Pharmaceuticals INC. | $17.13 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.63 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.85 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.44 | 2023 | Keveyis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.11 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.03 | 2023 | Xifaxan |
| Mylan Specialty L.P. | $13.90 | 2020 | |
| Phathom Pharmaceuticals, INC. | $13.33 | 2024 | Voquezna |
| Cranial Technologies, INC | $11.63 | 2022 | |
| Athena Bioscience, LLC | $6.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.